- Home
- RMCF vs ERNA Comparison
RMCF vs ERNA Comparison
Compare RMCF & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- ERNA
- Stock Information
- Founded
- RMCF 1981
- ERNA 2018
- Country
- RMCF United States
- ERNA United States
- Employees
- RMCF N/A
- ERNA N/A
- Industry
- RMCF Specialty Foods
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- ERNA Health Care
- Exchange
- RMCF Nasdaq
- ERNA Nasdaq
- Market Cap
- RMCF 11.6M
- ERNA 13.5M
- IPO Year
- RMCF N/A
- ERNA N/A
- Fundamental
- Price
- RMCF $1.48
- ERNA $1.50
- Analyst Decision
- RMCF
- ERNA
- Analyst Count
- RMCF 0
- ERNA 0
- Target Price
- RMCF N/A
- ERNA N/A
- AVG Volume (30 Days)
- RMCF 22.7K
- ERNA 37.0K
- Earning Date
- RMCF 10-14-2025
- ERNA 08-13-2025
- Dividend Yield
- RMCF N/A
- ERNA N/A
- EPS Growth
- RMCF N/A
- ERNA N/A
- EPS
- RMCF N/A
- ERNA N/A
- Revenue
- RMCF $29,545,000.00
- ERNA $488,000.00
- Revenue This Year
- RMCF N/A
- ERNA N/A
- Revenue Next Year
- RMCF N/A
- ERNA N/A
- P/E Ratio
- RMCF N/A
- ERNA N/A
- Revenue Growth
- RMCF 5.81
- ERNA 201.24
- 52 Week Low
- RMCF $1.12
- ERNA $1.48
- 52 Week High
- RMCF $3.49
- ERNA $28.80
- Technical
- Relative Strength Index (RSI)
- RMCF 42.85
- ERNA 33.87
- Support Level
- RMCF $1.39
- ERNA $1.55
- Resistance Level
- RMCF $1.53
- ERNA $1.70
- Average True Range (ATR)
- RMCF 0.10
- ERNA 0.09
- MACD
- RMCF -0.01
- ERNA 0.00
- Stochastic Oscillator
- RMCF 33.48
- ERNA 7.69
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.